English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 25 August 2020, 11:55 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch Sahne Medical Spray and Sahne Medical Cream
Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care products

Sahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid

TOKYO, Aug 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched Sahne Medical Spray and Sahne Medical Cream (both are category-2 OTC drugs, "Sahne Medical") on August 25, 2020 at pharmacies and drugstores throughout Japan, as a new product of the Sahne brand lineup which has been a favored hand care for generations.




Eisai conducted a survey of 1,000 women in their 40s to 50s in April 2020. As a result, it was found that approximately 70% of the subjects felt that the dryness of their skin and/or the dry skin expanse had increased compared to its condition five years ago. Additionally, a number of comments regarding the discomfort of dryness from people with dry skin were received as follows: "The dryness has spread to my thighs, shins, sides, and back.", "I'm distracted just by my underwear rubbing against my skin.", and "My dry skin flakes stick inside my clothes whenever I get undressed, which makes me uncomfortable." It is considered that the skin condition of women after their late 30s requires more reliable moisturizing effects of pharmaceuticals, since the amounts of sebum, natural moisturizing factors, and intercellular lipids in the stratum corneum necessary for water retention of the skin decrease.

"Sahne Medical" is a category-2 OTC drug containing the active ingredient "Heparinoid", which exerts a high moisturizing effect against dry skin (xeroderma) that worsens with age. Heparinoid penetrates into the stratum corneum, increases natural moisturizing factors, and restores the structure of intercellular lipids in the stratum corneum to moisturize dry skin.

There are two types of product lines, spray and cream, which can be selected depending on the part of the body where the product is applied and/or the principles of TPO (time, place and occasion). "Sahne Medical Spray" is the first OTC drug spray-type lotion containing Heparinoid. This product is handy for the consumer to use on the back, side and back of thigh, where it is difficult to apply the medicine by themselves, as it features a container that can be sprayed upside down and a fine mist-like lotion. In addition, the tube-type "Sahne Medical Cream" is recommended for relieving unbearable discomfort of dryness upon going out, as it is convenient to carry.

The Sahne brand has continued to be a gentle companion to the daily lives of many people for 66 years since its launch. With the new launch of Sahne Medical, a pharmaceutical product, Eisai is now able to provide a remedy for skin problems that it had not been able to contribute to before. Eisai will further respond to the wishes of consumers who want to be relieved of the discomfort of dry skin, with the moisturizing effect of pharmaceutical care products and the gentle nature of Sahne products.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Releated News
Oct 28, 2020 11:00 HKT/SGT
エーザイとJD Health、中国における健康サービスプラットフォーム構築に向けた合弁会社を設立
Oct 28, 2020 09:07 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference
Oct 28, 2020 09:00 HKT/SGT
エーザイ、第13回アルツハイマー病臨床試験会議(CTAD)においてアルツハイマー病/認知症領域の開発品に関する最新データを発表
Oct 28, 2020 08:01 HKT/SGT
Eisai and JD Health Establish JV Company in China to Implement Health Service Platform
Oct 27, 2020 09:00 HKT/SGT
Global Coalition for Adaptive Research・アムジェン・エーザイ、COVID-19グローバル試験に最初の患者様が登録されたことを発表
More news >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575